Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
LetterCorrespondence

High-titer Anti-aquaporin-4-IgG-associated Myelitis in Rhupus Syndrome

SAVINO SCIASCIA, DARIO ROCCATELLO, DANIELA ROSSI, ALESSANDRA RUSSO, MADALINA OANA MEREUTA and ROBERTO CAVALLO
The Journal of Rheumatology April 2012, 39 (4) 871-873; DOI: https://doi.org/10.3899/jrheum.110873
SAVINO SCIASCIA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: savino.sciascia@unito.it
DARIO ROCCATELLO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DANIELA ROSSI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ALESSANDRA RUSSO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MADALINA OANA MEREUTA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ROBERTO CAVALLO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

To the Editor:

Severe organ damage, especially central nervous system (CNS) involvement, has rarely been reported in patients with rhupus syndrome (RS). Two recent articles in The Journal of Rheumatology1,2 have discussed this condition, which is a challenge in rheumatology.

A 51-year-old woman was referred to our center for longstanding polyarthralgia, fever, malaise, and malar rash associated with a history of neurological abnormalities.

In 1999 the patient felt a sudden pain in her back between the shoulder blades and then developed weakness of the upper extremities and paresthesias at the lower ones. No urinary symptoms were found. During the physical examination a decrease of arm strength was recorded, and a loss of sense of touch and of pain from the nipples through the feet. Scans of T2-weighted sequences of magnetic resonance imaging (MRI) of the spine showed a hyperintense lesion involving the medulla from level C5 to T7. An MRI scan of the brain was normal. Examination of the cerebrospinal fluid showed a high protein content and pleocytosis. Neither viruses nor bacteria nor oligoclonal IgG bands were found. A diagnosis of aseptic myelitis was made and she was treated with high doses of intravenous steroids. This treatment resulted in healing of a spinal cord lesion — an MRI of the spine done 6 months later showed that the length of the lesion had clearly decreased. In 2010, when she came to our center, a neurological examination showed hypopallesthesia from the T1 level. An MRI scan of the spine confirmed the well known T2-hyperintense medullary lesion from T1 to T5. Brain MRI and visual evoked potential were normal. High-titer anti-aquaporin-4-IgG (NMO-IgG) was also reported. However, the diagnosis of neuromyelitis optica (NMO) was not supported by clinical and electrophysiological investigations. About 2 months after admission to our center, she still had polyarthralgia, fever, malaise, and malar rash (Figure 1A), with photosensitivity and oral aphthosis. Her immunological profile was characterized by positivity for antinuclear antibody (1:160, granular pattern), anti-dsDNA, anticitrullinated protein antibodies (47.95 U/ml), and rheumatoid factor, along with an erosive radiograph-documented polyarthritis (Figure 1B). The clinical setting and the serological profile were consistent with a diagnosis of RS. She was treated with hydroxychloroquine, azathioprine (50 mg/day), and low-dose prednisone, and a year after the RS diagnosis, she was in good health, with maintenance therapy.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Clinical features of systemic lupus erythematosus (A, malar rash) and rheumatoid arthritis (B, radiograph-documented erosive polyarthritis), consistent with diagnosis of rhupus syndrome.

RS is a rare clinical condition characterized by overlapping clinical and immunologic features of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)3. Whether RS is a clinically and immunologically distinctive entity4, a coincidental concurrence5, or a subgroup of patients with SLE6 remains somewhat controversial.

Severe CNS involvement is rare in patients with RS4. We speculate whether our patient’s previous episode of myelitis could represent an isolated coincidental neurological manifestation not related to RS or whether it could be interpreted as neuropsychiatric involvement secondary to the autoimmune disease. Moreover, isolated connective tissue disease-related nervous system impairment can mimic other neurologic disorders, resulting in misdiagnosis and unfavorable clinical outcome, mainly in rare conditions such as RS. Myelopathy is a rare but severe neurological manifestation of SLE. The etiology is not completely understood, but antiphospholipid antibodies (aPL) are presumed to be involved7. Nevertheless, besides aPL, cytokine- and autoantibody-mediated neuronal dysfunction have been suggested as underlying processes in neuropsychiatric SLE.

Idiopathic longitudinally extensive myelitis is an NMO spectrum disorder and patients with NMO often have an accompanying autoimmune disease, usually SLE. The autoantibody NMO-IgG is detectable in patients with NMO, but also in a high proportion of patients with an NMO spectrum disorder. A pathogenetic role for the NMO-IgG is well known8 and the specificity of NMO-IgG for differentiating patients with NMO or NMO spectrum disorder from patients with multisystem autoimmune disorder associated with other neurological syndromes has been thoroughly assessed9. Hence NMO-IgG is not a nonspecific companion of SLE.

The presence of NMO-IgG in this clinical setting demonstrates that NMO can accompany RS, just as SLE can. Moreover, the evidence of autoantibodies against aquaporin-4 bears important diagnostic and prognostic implications and could also guide critical therapeutic decisions. In fact, early use of immunosuppressive therapy is thought to help patients with NMO10. Certainly, the complex autoimmune profile of our patient makes the interpretation and the clinical relevance of NMO-IgG positivity controversial.

Predominant RA manifestations in patients with RS are erosive arthropathy, with almost half the cases having rheumatoid nodules. At the time of appearance of SLE manifestations, these are characterized by cutaneous and hematological alterations with mild renal damage4. Neurologic involvement in patients with RS is very uncommon. But a rapid diagnosis of this disorder is essential because connective tissue disease-related transverse myelopathy has a poor prognosis, and neurological recovery is more likely with prompt, aggressive treatment with high-dose corticosteroids and cytotoxic agents.

To date, the coexistence of RS associated with neuromyelitis has not been convincingly reported in English-language scientific literature. Our case documents the possible association between these rare conditions, in a complex autoimmune mosaic.

REFERENCES

  1. 1.↵
    1. Chogle AR,
    2. Shah CV,
    3. Murthy AK
    . Role of anti-tumor necrosis factor-alpha blockers in inducing lupus erythematosus tumidus in “rhupus syndrome”. J Rheumatol 2011;38:1218–9.
    OpenUrlFREE Full Text
  2. 2.↵
    1. Prabhakaran S,
    2. Handler RP
    . Lupus, “rhupus” and “sjrupus”. J Rheumatol 2011;38:393.
    OpenUrlFREE Full Text
  3. 3.↵
    1. Kantor G,
    2. Bickel Y,
    3. Barnett E
    . Coexistence of systemic lupus erythematosus and rheumatoid arthritis. Report of a case and review of the literature, with clinical, pathologic and serologic observations. Am J Med 1969;47:433–44.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Simon JA,
    2. Granados J,
    3. Cabiedes J,
    4. Morales JR,
    5. Varela JA
    . Clinical and immunogenetic characterization of Mexican patients with ‘rhupus’. Lupus 2002;11:287–92.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. van Vugt RM,
    2. Derksen RH,
    3. Kater L,
    4. Bijlsma JW
    . Deforming arthropathy or lupus and rhupus hands in systemic lupus erythematosus. Ann Rheum Dis 1998;57:540–4.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Fernandez A,
    2. Quintana G,
    3. Matteson EL,
    4. Restrepo JF,
    5. Rondón F,
    6. Sánchez A,
    7. et al.
    Lupus arthropathy: Historical evolution from deforming arthritis to rhupus. Clin Rheumatol 2004;23:523–6.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Kovacs B,
    2. Lafferty TL,
    3. Brent LH,
    4. DeHoratius RJ
    . Transverse myelopathy in systemic lupus erythematosus: An analysis of 14 cases and review of the literature. Ann Rheum Dis 2000;59:120–4.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Lennon VA,
    2. Kryzer TJ,
    3. Pittock SJ,
    4. Verkman AS,
    5. Hinson SR
    . IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202:473–7.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Pittock SJ,
    2. Lennon VA,
    3. de Seze J,
    4. Vermersch P,
    5. Homburger HA,
    6. Wingerchuk DM,
    7. et al.
    Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 2008;65:78–83.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Jacob A,
    2. Weinshenker BG,
    3. Violich I,
    4. McLinskey N,
    5. Krupp L,
    6. Fox RJ,
    7. et al.
    Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008;65:1443–8.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 39, Issue 4
1 Apr 2012
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
High-titer Anti-aquaporin-4-IgG-associated Myelitis in Rhupus Syndrome
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
High-titer Anti-aquaporin-4-IgG-associated Myelitis in Rhupus Syndrome
SAVINO SCIASCIA, DARIO ROCCATELLO, DANIELA ROSSI, ALESSANDRA RUSSO, MADALINA OANA MEREUTA, ROBERTO CAVALLO
The Journal of Rheumatology Apr 2012, 39 (4) 871-873; DOI: 10.3899/jrheum.110873

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
High-titer Anti-aquaporin-4-IgG-associated Myelitis in Rhupus Syndrome
SAVINO SCIASCIA, DARIO ROCCATELLO, DANIELA ROSSI, ALESSANDRA RUSSO, MADALINA OANA MEREUTA, ROBERTO CAVALLO
The Journal of Rheumatology Apr 2012, 39 (4) 871-873; DOI: 10.3899/jrheum.110873
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Dr. Kitajima et al reply
  • Dr. Putman et al reply
  • Drs. Chung and McMahan reply
Show more Correspondence

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire